No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation.
| Citation | Harati, Hadi, et al. “No Evidence of a Causal Association of Type 2 Diabetes and Glucose Metabolism With Atrial Fibrillation”. 2019. Diabetologia, vol. 62, no. 5, 2019, pp. 800–804. | 
| Center | Stanford University | 
| Author | Hadi Harati, Daniela Zanetti, Abhiram Rao, Stefan Gustafsson, Marco Perez, Erik Ingelsson, Joshua W Knowles | 
| Keywords | atrial fibrillation, Genome-wide association, Mendelian randomisation, type 2 diabetes | 
| Abstract | AIMS/HYPOTHESIS: Several epidemiological studies have shown an increased risk of atrial fibrillation in individuals with type 2 diabetes or milder forms of dysglycaemia. We aimed to assess whether this relation is causal using a Mendelian randomisation approach. METHODS: Two-sample Mendelian randomisation was used to obtain estimates of the influence of type 2 diabetes, fasting blood glucose (FBG), and HbA on the risk of atrial fibrillation. Instrumental variables were constructed using available summary statistics from meta-analyses of genome-wide association studies (GWAS) for type 2 diabetes and associated phenotypes. Pleiotropic SNPs were excluded from the analyses. The most recent GWAS meta-analysis summary statistics for atrial fibrillation, which included over 1 million individuals (approximately 60,000 individuals with atrial fibrillation) was used for outcome analysis. RESULTS: Neither type 2 diabetes (OR 1.01 [95% CI 0.98, 1.03]; p = 0.37), nor FBG (OR 0.95 [95% CI 0.82, 1.09] per mmol/l; p = 0.49) or HbA (OR 1.01 [95% CI, 0.85, 1.17] per mmol/mol [%]; p = 0.88) were associated with atrial fibrillation in Mendelian randomisation analyses. We had >80% statistical power to detect ORs of 1.08, 1.06 and 1.09 or larger for type 2 diabetes, FBG and HbA, respectively, for associations with atrial fibrillation. CONCLUSIONS/INTERPRETATION: This Mendelian randomisation analysis does not support a causal role of clinical significance between genetically programmed type 2 diabetes, FBG or HbA and development of atrial fibrillation. These data suggest that drug treatment to reduce dysglycaemia is unlikely to be an effective strategy for atrial fibrillation prevention. DATA AVAILABILITY: The datasets analysed during the current study are available from the following repository: Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al (2018) GWAS summary statistics for AF (N=60,620 AF cases and 970,216 controls). Center for Statistical Genetics: http://csg.sph.umich.edu/willer/public/afib2018/nielsen-thorolfsdottir-…. | 
| Year of Publication | 2019 | 
| Journal | Diabetologia | 
| Volume | 62 | 
| Issue | 5 | 
| Number of Pages | 800-804 | 
| Date Published | 12/2019 | 
| ISSN Number | 1432-0428 | 
| DOI | 10.1007/s00125-019-4836-y | 
| Alternate Journal | Diabetologia | 
| PMCID | PMC6451665 | 
| PMID | 30810766 | 
| Download citation |